Special guest post by Nicholas J. Diamond
Medicaid is currently facing a timely, although largely underappreciated, challenge: rebalancing Medicaid long-term services and supports (LTSS). For context, LTSS refer to a broad range of paid and unpaid medical and personal care assistance for individuals who experience difficulty completing self-care tasks due to aging, chronic illness, or disability. According to 2013 estimates, there are approximately 12 million individuals in the U.S. who rely on LTSS, mostly paid for through Medicaid, with a projected increase to approximately 27 million individuals by 2050.
Medicaid has a historical structural bias toward institutional care, such as nursing homes, as opposed to home and community-based services (HCBS), such as home health aides, personal care, chore services, supported employment, rent and food for live-in caregiver, and nonmedical transportation, among many others. Medicaid LTSS rebalancing, therefore, shifts spending away from institutional settings and toward HCBS, which is less expensive and generally preferred by beneficiaries. States may provide HCBS through a complex panoply of federal statutory authorities, including waiver authorities, which afford states wide latitude in designing programs. As you might imagine, with flexibility comes significant variations in how states provide HCBS, which specific types of HCBS they provide, and whether, for instance, cost containment strategies available under certain authorities negatively impact access to needed services. Continue reading
BioData World Congress USA 2016
September 14-15, 2016
Hyatt Regency, Boston, MA
BioData World Congress USA is the world’s leading event for individuals working with Big Data in precision medicine.
The two day conference will feature case study applications of Big Data and Genomics to drive precision medicine into the clinic through the assembly of the multidisciplinary cohort involved in the delivery of the Precision Medicine
The event will cover a range of different topics including:
- How to manage data generated in bioinformatics
- How to utilise NGS to develop more targeted therapeutics
- How to practically apply genomic data in precision medicine
- Utilizing the Cloud for collaborative research
- Developing secure information systems
- Ethical considerations in the sharing of genomic data
- How to transition big data into the clinic
- How to access open source technologies in LS research
- How to apply big data analytics to mine information
Click here for more information, including how to register.
Part Five of Seven-Part Blog Series by Guest Blogger Patrick Taylor
The preamble to the NPRM justifies requiring consent for data and specimen research by contending that studies indicate that people want to be asked for permission. However, the literature on this topic is relatively thin. Available evidence suggests that many people, upon being informed that their heath data and tissues could or would be used in research without their consent (and nothing further is said to prompt the idea that research might delve into controversial matters) are generally fine with such use. But when also queried whether they would prefer to have been asked, people say they would. What the literature does not show is that people say: “I object to any use without my consent,” let alone “and I choose that over all the advantages of minimal risk research involving analysis by a computer of digitized files not humanly readable limited to disease-gene associations of thousands of medical records where consent would not be possible but the results will be essential or important to my health, the health of others, and the national health.” Pluralistic discussion of tradeoffs over time, or an extended, candid national dialogue about the reasons for the present rules, were not in the mix. Yet still, people said the opposite of “This must not occur without my consent!”
We have already seen one way in which the claim to be respecting the preference to be asked is untrue – it applies to only some research by some organizations. Now here is another. The commentaries to the NPRM celebrate as fact that a patient need be asked only once, for all time, and then the only acceptable “yes” answer grants permission for any research by anybody. It seems doubtful that a one-time consent to any future scientific research by any researcher for any purpose, without ever going back to inform or re-query, without any regulatory provisions ensuring it was revocable, was what participants meant by “being asked.” Rationally, that option is far worse than no consent, for reasons we shall come to. Continue reading